Aziz Ali Sumera, Genkinger Jeanine, Kahe Ka, Valeri Linda, Khowaja Nayab, Krebs Nancy F, Kuhn Louise
Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY, USA.
Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.
Syst Rev. 2025 Jan 13;14(1):11. doi: 10.1186/s13643-024-02726-7.
Impaired intrauterine growth, a significant global health problem, contributes to a higher burden of infant morbidity and mortality, mainly in resource-poor settings. Maternal anemia and undernutrition, two important causes of impaired intrauterine growth, are prioritized by global nutrition targets of 2030. We synthesized the evidence on the role of preconception nutrition supplements in reducing maternal anemia and improving intrauterine growth.
We undertook a review of the randomized controlled trials (RCTs) assessing the effect of preconception nutrition supplements on maternal hemoglobin, an indicator to estimate maternal anemia, and markers of intrauterine growth including birth weight, length, head circumference, and small for gestational age. Additionally, we examined preterm birth as an important perinatal outcome. We searched PubMed, CINAHL, Web of Science, Cochrane Central, and Embase. We computed summary mean differences and risk ratios (RR) with 95% confidence intervals (CIs) using random-effect models. We employed I and Cochran's Q test statistics to assess heterogeneity. We used a revised Cochrane risk-of-bias (RoB version 2.0) and GRADE (grading of recommendations, assessment, development, and evaluation) tools to assess the risk of bias and quality of evidence of eligible RCTs, respectively.
We identified 20 eligible RCTs (n = 27,659 women). Preconception nutrition supplements (iron and folic acid, multiple micronutrients, and a lipid-based nutrient supplement) overall increased maternal hemoglobin by 0.30 g/dL ((0.03, 0.57); I = 79%; n=9). However, we did not find a significant effect of the supplements on birth weight (12.25 gm ((- 22.66, 47.16); I = 55%; n=10)), length (0.15 cm (- 0.26, 0.56); I = 68%; n = 5), head circumference (- 0.23 cm (- 0.88, 0.43); I = 84%; n=4), small for gestational age (RR 0.91 (0.80, 1.04); I = 31%; n=8), or preterm birth (RR 0.93 (0.69,1.25); I = 57%; n=12). In general, the quality of evidence was assessed as very low to moderate.
Preconception nutrition supplements studied to date appear to reduce maternal anemia. However, it is uncertain whether there are beneficial effects of the supplements on intrauterine growth. Low quality of evidence warrants future well-designed RCTs to produce solid scientific data, particularly of a more comprehensive package of preconception nutrition supplements that include both macro- and micronutrients.
PROSPERO CRD42023464966.
子宫内生长受限是一个重大的全球健康问题,主要在资源匮乏地区导致婴儿发病和死亡负担加重。孕产妇贫血和营养不良是子宫内生长受限的两个重要原因,被纳入2030年全球营养目标的优先事项。我们综合了关于孕前营养补充剂在降低孕产妇贫血和改善子宫内生长方面作用的证据。
我们对随机对照试验(RCT)进行了综述,评估孕前营养补充剂对孕产妇血红蛋白(估计孕产妇贫血的指标)以及子宫内生长指标(包括出生体重、身长、头围和小于胎龄儿)的影响。此外,我们将早产作为一个重要的围产期结局进行了研究。我们检索了PubMed、CINAHL、科学网、Cochrane中心和Embase。我们使用随机效应模型计算了汇总平均差和风险比(RR)以及95%置信区间(CI)。我们采用I²和Cochran's Q检验统计量评估异质性。我们分别使用修订后的Cochrane偏倚风险(RoB版本2.0)和GRADE(推荐分级、评估、制定和评价)工具评估符合条件的RCT的偏倚风险和证据质量。
我们确定了20项符合条件的RCT(n = 27659名女性)。孕前营养补充剂(铁和叶酸、多种微量营养素以及基于脂质的营养补充剂)总体上使孕产妇血红蛋白增加了0.30 g/dL((0.03, 0.57);I² = 79%;n = 9)。然而,我们未发现补充剂对出生体重(12.25克((-22.66, 47.16);I² = 55%;n = 10))、身长(0.15厘米(-0.26, 0.56);I² = 68%;n = 5)、头围(-0.23厘米(-0.88, 0.43);I² = 84%;n = 4)、小于胎龄儿(RR 0.91 (0.80, 1.04);I² = 31%;n = 8)或早产(RR 0.93 (0.69, 1.25);I² = 57%;n = 12)有显著影响。总体而言,证据质量被评估为极低到中等。
迄今为止研究的孕前营养补充剂似乎能降低孕产妇贫血。然而,补充剂对子宫内生长是否有有益影响尚不确定。证据质量低,需要未来设计良好的RCT来产生可靠的科学数据,特别是关于更全面的孕前营养补充剂组合(包括宏量和微量营养素)的数据。
PROSPERO CRD42023464966。